Approach to pneumococcal vaccination in children ages 6 through 18 years with high-risk conditions

This algorithm summarizes our suggested approach to pneumococcal vaccination in children ages 6 to 18 years of age with high-risk conditions (as defined in Inset 2 above). Children with these conditions are at high risk of IPD. The vaccination schedule is determined by the child's prior vaccination history with PCV13/PCV15/PCV20 (doses of PCV7 are not counted) and the nature of the high-risk condition. This algorithm is intended for use in conjunction with other UpToDate content. For additional details, including information about the efficacy of pneumococcal vaccines, refer to UpToDate's topic on pneumococcal vaccination in children.

IPD: invasive pneumococcal disease; PCV: pneumococcal conjugate vaccine; PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.

* For immunocompromised children (including those with asplenia) who receive PPSV23, the Advisory Committee on Vaccine Practices recommends a total of 2 doses. However, some experts suggest that children with asplenia receive PPSV23 every 5 years. Some experts recommend an interval of 3 years between PPSV23 doses for children with sickle cell disease.

¶ Refer to separate UpToDate content for guidance on pneumococcal vaccination following hematopoietic cell transplantation.

Graphic 119305 Version 8.0

خرید پکیج

Approach to pneumococcal vaccination in children ages 6 through 18 years with high-risk conditions